NASDAQ · BNGO
Healthcare · Medical - Diagnostics & Research
$1.15
Up+$0.05 (+4.55%)
Updated Nov 7, 2026, 11:27 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BNGO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
BNGO closed at $1.15 after 21 trading sessions, down 19.86% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $1.13 | $1.15 | $1.10 | $1.15 | 97.02K |
| Nov 5, 2026 | $1.19 | $1.19 | $1.0701 | $1.10 | 394.39K |
| Nov 4, 2026 | $1.21 | $1.22 | $1.18 | $1.19 | 72.18K |
| Nov 3, 2026 | $1.16 | $1.20 | $1.16 | $1.20 | 130.92K |
| Nov 2, 2026 | $1.17 | $1.1898 | $1.14 | $1.16 | 89.12K |
| Oct 30, 2026 | $1.18 | $1.20 | $1.12 | $1.15 | 196.43K |
| Oct 29, 2026 | $1.20 | $1.205 | $1.18 | $1.20 | 67.19K |
| Oct 28, 2026 | $1.23 | $1.25 | $1.195 | $1.205 | 114.37K |
| Oct 27, 2026 | $1.19 | $1.22 | $1.15 | $1.22 | 73.59K |
| Oct 26, 2026 | $1.15 | $1.165 | $1.135 | $1.16 | 62.37K |
| Oct 23, 2026 | $1.18 | $1.18 | $1.10 | $1.13 | 251.96K |
| Oct 22, 2026 | $1.26 | $1.2997 | $1.17 | $1.18 | 443.18K |
| Oct 21, 2026 | $1.26 | $1.28 | $1.25 | $1.25 | 131.67K |
| Oct 20, 2026 | $1.21 | $1.32 | $1.21 | $1.245 | 433.15K |
| Oct 19, 2026 | $1.27 | $1.2899 | $1.22 | $1.22 | 133.41K |
| Oct 16, 2026 | $1.39 | $1.39 | $1.25 | $1.25 | 181.14K |
| Oct 15, 2026 | $1.38 | $1.40 | $1.3303 | $1.37 | 92.73K |
| Oct 14, 2026 | $1.37 | $1.4199 | $1.36 | $1.37 | 158.29K |
| Oct 13, 2026 | $1.34 | $1.40 | $1.31 | $1.36 | 187.15K |
| Oct 12, 2026 | $1.41 | $1.42 | $1.2903 | $1.345 | 487.7K |
| Oct 9, 2026 | $1.45 | $1.50 | $1.4301 | $1.435 | 129.4K |
The latest Smart Investors Daily articles mentioning BNGO.
Company
Market Activity
Research & News
BNGO research
Company profile and research snapshot.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 13, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 24, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 18, 2025 | HC Wainwright & Co. | Buy | — |
| May 20, 2025 | Maxim Group | Buy | — |
| Apr 9, 2025 | HC Wainwright & Co. | Buy | — |
Generated Nov 7, 2026, 11:02 AM
Bionano Genomics (BNGO) gained 4.55% today, rising $0.05 per share in modest trading activity. While no direct company-specific news drove the move, the gain suggests modest investor optimism, though trading volume and catalysts remain limited.
Bottom line: BNGO's modest 4.55% gain today appears driven by technical factors or sector sentiment rather than company-specific news, with the Sarepta headline serving as a potential backdrop for biotech rotation. Investors should monitor for upcoming clinical data, commercial partnerships, or adoption metrics that would validate the company's long-term growth thesis, while remaining cautious about the stock's limited near-term catalysts and execution risks.
Yahoo · Nov 6, 2026
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -64.87% and +9.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 27, 2026
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, November 10, 2026, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2026 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, November 10th, 2026Time:4:30 p.m. ETParticipant Link:Registration – click hereWebcast:Registration – click here Participants may access a live w
Yahoo · Sep 23, 2026
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced expansion of optical genome mapping (OGM) based testing of hematologic malignancies at Memorial Sloan Kettering Cancer Center (MSK), following approval from the New York State Department of Health (NYSDOH). Hematologic cancers, including acute leukemias, myelodysplastic syndromes (MDS),
Benzinga · Sep 15, 2026
Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BNGO.
